Shamburg News · 8-K filed Oct 20, 2026, 4:57 PM EDT
Inhibikase Therapeutics Appoints Scott Wasserman to Board; Dennis Berman Resigns
IKT · Inhibikase Therapeutics, Inc.
- Leadership change
- Reg FD disclosure
- Other event
- Materiality: medium
On October 19, 2026, Inhibikase Therapeutics, Inc. appointed Scott Wasserman, MD, as a Class III director and member of the Compensation Committee, effective October 19, 2026, and the Board determined he is independent. Dennis Berman resigned from the Board and as Chair of the Compensation Committee and member of the Audit Committee, effective October 19, 2026, stating no disagreement with the Company. Dr. Wasserman will receive an initial new director grant of non-qualified stock options to purchase up to 310,000 shares of common stock, along with cash compensation under the Company's director compensation policy.
Source: SEC EDGAR, Form 8-K, Items 5.02, 7.01, 9.01, accession 0001193125-26-426811.
Written from the filing by Shamburg Markets. Figures are as reported by the company.